Page 3 - Assembly Bio News Today

SOUTH SAN FRANCISCO, Calif., May 23, 2023 -- Assembly Biosciences, Inc. , a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that... | May 23, 2023

Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and... | April 18, 2023

This platform randomized clinical trial examines the effectiveness ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the treatment of e

24.10.2022 - Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement ... Seite 1

Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM​, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical... | June 21, 2022

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company...

ABUS earnings call for the period ending March 31, 2022.

ABUS earnings call for the period ending March 31, 2022.

Game-changing therapies have made the WHO goal of achieving hepatitis C elimination by 2030 possible, but many countries find themselves fighting an uphill battle, according to experts.“In 2019 to 2020, WHO estimated there were 50 million persons living with chronic HCV, of whom 1.4 million were persons who inject drugs and 2.3 million were coinfected with HIV. New infections were

/PRNewswire/ -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical...